Krystal Biotech Inc KB301 Phase 1 POC Efficacy Data Update Call Transcript
Good morning, everyone, and welcome to Jeune Aesthetics and Krystal Biotech call and webcast discussing from the second cohort of Phase I PEARL-1 trial of intradermal KB301 for the treatment of aesthetic skin conditions. (Operator Instructions) Today's call is being recorded.
At this time, I would like to turn the call over to Krish Krishnan, Chairman and CEO. Please go ahead.
Good morning. Thank you for joining us today. We're going to be reviewing the second cohort of the PEARL-1 trial of intradermal KB301 for the improvement of skin quality, which we announced earlier this morning. Next slide.
As a reminder, this presentation will contain forward-looking statements based on our current expectations and beliefs. Such statements are subject to a number of risks that could cause actual results to differ materially. We refer you to our SEC filings for further information. Next slide.
So we here at Jeune and Krystal are excited to talk to you all about
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |